Addressing Suboptimal Anti-VEGF Response in Neovascular AMD and DME

July 1, 2024

By Hong-Uyen Hua, MD
Sruthi Arepalli, MD

Opinion

Podcast

A panel of ophthalmologists discuss strategies for managing AMD and DME patients who exhibit suboptimal responses to their current anti-VEGF therapy.

1:00 Suboptimal Response
6:30 Treatment Strategy
11:10 Response to New Therapies
14:00 Imaging for Monitoring
18:30 Role of Ang-2

Related Videos

Viability of Elamipretide for Geographic Atrophy in Dry AMD | Image Credit: HCPLive

Advancing Elamipretide into Phase 3 ReNEW and ReGAIN Trials | Image Credit: HCPLive

Elamipretide in ReCLAIM-2 Trial | Image Credit: HCPLive

Hong-Uyen Hua, MD; Sruthi Arepalli, MD; and Peter Kaiser, MD

Cindy X. Cai, MD: Impact of Race, Neighborhood on Diabetic Retinopathy Care | Image Credit: Johns Hopkins University

Dimitra Skondra, MD, PhD: Protective Effect of Metformin in Geographic Atrophy| Image Credit: University of Chicago

Deepak Sambhara, MD | Image Credit: American Society of Retina Specialists

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.